Literature DB >> 22373697

Calreticulin signaling in health and disease.

Wen-An Wang1, Jody Groenendyk, Marek Michalak.   

Abstract

Calreticulin is an endoplasmic reticulum Ca(2+) binding chaperone that has multiple functions inside and outside of the endoplasmic reticulum. It is involved in the quality control of newly synthesized proteins and glycoproteins, interacting with various other endoplasmic reticulum chaperones, specifically calnexin and ER protein of 57-kDa in the calreticulin/calnexin cycle. Calreticulin also plays a crucial role in regulating intracellular Ca(2+) homeostasis, associating calreticulin with a wide variety of signaling processes, such as cardiogenesis, adipocyte differentiation and cellular stress responses. The role of calreticulin outside of the endoplasmic reticulum is also extensive, including functions in wound healing and immunity. Therefore, calreticulin has important implications in health and disease. Signaling facts.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22373697     DOI: 10.1016/j.biocel.2012.02.009

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  73 in total

1.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.

Authors:  A Tefferi; T L Lasho; C M Finke; R A Knudson; R Ketterling; C H Hanson; M Maffioli; D Caramazza; F Passamonti; A Pardanani
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

Review 2.  Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.

Authors:  Jamile M Shammo; Brady L Stein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

3.  Low frequency of calreticulin mutations in MDS patients.

Authors:  M Heuser; V Panagiota; C Koenecke; B Fehse; H Alchalby; A Badbaran; R Shahswar; M Stadler; M Eder; G Göhring; A Trummer; T Schroeder; G Kobbe; C Thiede; U Platzbecker; B Schlegelberger; N Kroeger; A Ganser; F Thol
Journal:  Leukemia       Date:  2014-05-21       Impact factor: 11.528

4.  Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling.

Authors:  L Eder-Azanza; D Navarro; P Aranaz; F J Novo; N C P Cross; J L Vizmanos
Journal:  Leukemia       Date:  2014-06-12       Impact factor: 11.528

5.  Expression and intracytoplasmic distribution of staufen and calreticulin in maturing human oocytes.

Authors:  L De Santis; F Gandolfi; G Pennarossa; S Maffei; E Gismano; G Intra; M Candiani; T A L Brevini
Journal:  J Assist Reprod Genet       Date:  2015-01-27       Impact factor: 3.412

Review 6.  Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.

Authors:  Xavier Cahu; Stefan N Constantinescu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 7.  Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Authors:  L Falchi; H M Kantarjian; S Verstovsek
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

8.  Tax posttranslational modifications and interaction with calreticulin in MT-2 cells and human peripheral blood mononuclear cells of human T cell lymphotropic virus type-I-associated myelopathy/tropical spastic paraparesis patients.

Authors:  Fernando Medina; Sebastian Quintremil; Carolina Alberti; Andres Barriga; Luis Cartier; Javier Puente; Eugenio Ramírez; Arturo Ferreira; Yuetsu Tanaka; Maria Antonieta Valenzuela
Journal:  AIDS Res Hum Retroviruses       Date:  2014-01-24       Impact factor: 2.205

9.  Association of calreticulin expression with disease activity and organ damage in systemic lupus erythematosus patients.

Authors:  Yichao Wang; Jiaogui Xie; Zhili Liu; Hongwei Fu; Qianyu Huo; Yajun Gu; Yunde Liu
Journal:  Exp Ther Med       Date:  2017-03-20       Impact factor: 2.447

10.  Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer.

Authors:  Gautier Stoll; Kristina Iribarren; Judith Michels; Alexandra Leary; Laurence Zitvogel; Isabelle Cremer; Guido Kroemer
Journal:  Oncoimmunology       Date:  2016-06-09       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.